Clinical Trial: Thoracic Radiotherapy Plus EGFR-TKI for Stage III EGFR-mutant Lung Adenocarcinoma

U.S., Oct. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07857694) titled 'Thoracic Radiotherapy Plus EGFR-TKI for Stage III EGFR-mutant Lung Adenocarcinoma' on Sept. 29.

Brief Summary: Objective: To investigate the failure patterns, efficacy and safety of thoracic radiotherapy combined with EGFR-TKI in stage III unresectable non-small cell lung cancer harboring EGFR-sensitive mutations.

Methods: This is a multicenter retrospective cohort study. Patients diagnosed with stage III unresectable EGFR-mutant non-small cell lung cancer who received thoracic radiotherapy plus EGFR-TKI between January 1, 2020 and December 31, 2024 were enrolled from five hospitals in Guangxi, including Laibin People's Hospital, Th...